Latest Conference Articles

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

Alectinib shows promising long-term survival benefits over crizotinib in advanced ALK-positive lung cancer, highlighting significant clinical advancements.

Patients with metastatic hormone-sensitive prostate cancer report stable health-related quality of life while receiving niraparib and abiraterone acetate in the AMPLITUDE trial.

Lenvatinib combined with pembrolizumab and chemotherapy shows no significant survival benefit over pembrolizumab plus chemotherapy in metastatic esophageal cancer.

New findings reveal that adding durvalumab to chemotherapy enhances survival in muscle-invasive bladder cancer without harming quality of life.

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.

Sevabertinib shows promising efficacy in treating HER2-mutant advanced NSCLC, achieving high response rates and durable outcomes in clinical trials.

A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.

Anbenitamab plus chemotherapy significantly improves survival rates in HER2-positive gastric cancer patients, offering a promising new treatment option.

Durvalumab combined with FLOT chemotherapy significantly enhances overall survival in resectable gastric adenocarcinoma, establishing a new standard of care.

New research suggests using mpMRI for bladder cancer staging improves survival rates, potentially changing standard diagnostic practices.

Zongertinib shows promising results as a first-line treatment for advanced HER2-mutant NSCLC, achieving high response rates and significant clinical benefits.

A new treatment regimen for metastatic prostate cancer shows significant reductions in severe adverse events, offering a promising alternative for patients.

Dr. Joyce O'Shaughnessy discusses the monarchE trial's findings, emphasizing the importance of abemaciclib in reducing breast cancer recurrence and improving patient access.

Cevostamab delivered feasible and well-tolerated antitumor activities post CAR T-cell therapy in patients with heavily pretreated multiple myeloma.

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early breast cancer patients.

Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin.

Discover the most anticipated abstracts on gastrointestinal cancers at the 2025 ESMO Congress, featuring groundbreaking studies and innovative treatments.

A new study reveals a groundbreaking treatment for newly diagnosed multiple myeloma, achieving 100% response rates and minimal residual disease negativity.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.

New trial data shows ivonescimab combined with chemotherapy significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer patients.

Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.

Vote on the latest breakthroughs in renal and bladder cancer at ESMO 2025, featuring pivotal late-breaking abstracts.

Discover the most anticipated late-breaking abstracts in gastrointestinal cancers at ESMO 2025 and influence the conversation in oncology research.

New findings reveal zongertinib's effectiveness against brain metastases in HER2-mutant non–small cell lung cancer, offering hope for better treatment options.